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knowledge of the FDA-approved indications of commonly prescribed drugs, and to 
assess whether physicians’ belief that an indication is FDA-approved increases with
level of evidence supporting such use. METHODS: We conducted a national random 
sample mail survey of 599 primary care physicians and 600 psychiatrists conducted 
from November 2007 through August 2008. Physicians were presented with 14 drug-
indication pairs (e.g., gabapentin [Neurontin] for diabetic neuropathy) that varied
in their FDA-approval status and levels of supporting evidence. The main outcome
measure was physicians’ knowledge of whether each drug was FDA-approved for the
indication in question. RESULTS: The adjusted response rate was 47%, and the mean 
(median) number of drugs examined that were prescribed during the previous 12 
months was 11 (12). The average respondent correctly identiﬁ ed the FDA-approval
status of just over half of the drug-indication pairs queried (mean 55%; median 57%). 
The proportion increased modestly (mean 59%, median 61%) when limited to drugs
the respondent reported having prescribed during the previous 12 months. There was 
a strong association between physicians’ belief that an indication was FDA-approved
and greater evidence supporting that use (Spearman’s rho 0.74, p  0.001). However, 
41% of physicians believed at least one drug-indication pair with uncertain or no 
supporting evidence (e.g., quetiapine [Seroquel] for dementia with agitation) was 
FDA approved. CONCLUSIONS: These ﬁ ndings highlight an important need for 
more effective methods to inform physicians about the evidence base, or lack thereof, 
for drugs they prescribe off label.
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OBJECTIVES: Prescription charges were abolished in Wales in April 2007. We hypoth-
esised that as a result, the demand for prescription medicines might increase, and
compared the rates of dispensing of the 15 medicines that most frequently incurred a
prescription charge, versus a region with similar socio-economic characteristics that
continues to charge patients (NE England). METHODS: Monthly data from 2002 to
2008 (one year post abolition) on the quantities of dispensed medicines were obtained 
from Health Solutions Wales and the Prescription Pricing Authority. Descriptive com-
parative analyses of unadjusted dispensing rates (per 1000 list size) were conducted for 
each medicine. RESULTS: The combined dispensing rates for all 15 medicines increased 
signiﬁ cantly in both regions, but the change in Wales was higher than that in England 
(Wales change  57.67, p  0.0001, 95%CI  55.09 to 60.28; NE England change 
30.18, p  0.0001, 95%CI 27.32 to 33.03). The difference between regions was statisti-
cally signiﬁ cant (difference  27.51, p  0.0001, 95%CI 23.66 to 31.35). Whilst an 
expected widening of the difference between regions was apparent for some medicines,
factors beside the abolition of prescription charges are likely to account for the 
observed differences in others. For atenolol, a reduction in overall dispensing is
observed to coincide with trial evidence that cast doubts for its suitability as a ﬁ rst-line
drug for hypertension. The dispensing of co-codamol has risen dramatically in Wales, 
but not NE England, possibly related to different recommendations following the
withdrawal of co-proxamol. CONCLUSIONS: The abolition of prescription charges
is associated with changes in dispensing rates in Wales for some evaluated medicines.
However, the data require to be interpreted in the context of the low proportion of 
prescriptions that were previously charged, and changes in clinical practice.
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OBJECTIVES: To compare legislation on paediatric dosing guidelines and indications
between the US and Europe and to examine whether the introduction of new regula-
tions and ﬁ nancial incentives has resulted in more pharmaceutical companies provid-
ing paediatric data. METHODS: Information was extracted from published policies
and reports on paediatric therapeutics as published by the US Food and Drug Admin-
istration and the European Medicines Agency. RESULTS: In the US, the Food and
Drug Administration Modernisation Act (FDAMA; 1997) offered six months of mar-
keting exclusivity to manufacturers voluntarily conducting paediatric studies. Current 
legislation in the US consists of the Best Pharmaceuticals for Children Act (BPCA; 
2002), and the Paediatric Research Equity Act (PREA; 2003). Manufacturers are also
encouraged to obtain orphan drug designation for drugs or biological products for
use in a paediatric population. To January 2008, the FDA has sent written requests 
for paediatric studies to sponsors of 301 drugs. There have been 157 incidents of 
labeling changes under the BPCA and 76 labeling changes or submissions of support-
ing information under the PREA. Legislation on paediatric therapeutics was issued in
the EU in January 2007 (Regulation (EC) No 1901/2006 as amended). Since this time, 
the EMEA has adopted decisions on 99 applications for paediatric investigational 
plans (PIPs) and waivers; 57 positive opinions on PIPs; 3 proposed modiﬁ cations to
PIPs; and 39 waivers in all age groups for all conditions. Additionally, most European
Health Technology Assessment agencies do not make special allowances for the assess-
ment of paediatric therapeutics and dosing. CONCLUSIONS: The introduction of 
legislation in the US has been successful in encouraging research into the use of thera-
peutics in paediatric patients. In the EU, although many applications of PIPs and 
waivers have been reviewed, the situation should be monitored over the coming years 
to determine if the legislation leads to changes.
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OBJECTIVES: Across countries with varying political, socioeconomic and cultural 
environments, we sought to identify predictors of generic drug utilization. METHODS:
Data were collected from national and international regulatory agencies, MEDLINE
and internet searches for 37 countries classiﬁ ed as “advanced” or “emerging” econo-
mies by the International Monetary Fund: Argentina, Australia, Austria, Belgium, 
Brazil, Canada, China, Cyprus, Denmark, Finland, France, Germany, Greece, Iceland, 
India, Ireland, Israel, Italy, Japan, Luxembourg, Malta, Mexico, Netherlands, New
Zealand, Norway, Portugal, Russia, San Marino, Singapore, Slovenia, South Korea, 
Spain, Sweden, Switzerland, Taiwan, UK, United States. We compared the presence
of generic policies, ﬁ rst year of generic legislation, branded drug patent duration, 
proportion of generic drug utilization, and pricing for generics (government control, 
free market, or other), gross domestic product, and population across countries. Only 
independent variables with p  0.20 in univariate regression were included in the 
multivariate model: population, year of generic legislation, patent life, and pricing for 
generics (market vs. government control). RESULTS: Of 37 countries, data was avail-
able for 26 (70%): Argentina, Australia, Austria, Brazil, Belgium, Canada, Denmark, 
Finland, France, Germany, Greece, Ireland, Italy, Japan, Mexico, Netherlands, New 
Zealand, Norway, Portugal, Russia, Singapore, Spain, Sweden, Switzerland, UK and 
United States. Most countries enacted generic drug legislation in the 1990s, 9 (35%) 
introduced legislation before 1990, and 3 (12%) after 2000. Branded drug patent
duration was 15–20 years for 65% of countries. Among countries with generic drug 
laws, only free market-based generic pricing, compared to government-controlled 
pricing, was associated with a nominal increase in generic drug utilization (B  0.17, 
95% CI 0.01, 0.35). CONCLUSIONS: Countries with free market pricing policies 
had minimally greater diffusion of generic drugs compared to countries with govern-
ment pricing controls. Further investigation of other characteristics, namely the politi-
cal and social climates that foster greater generic drug utilization is planned.
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OBJECTIVES: To compare socioeconomic and behavioral characteristics of Medicare 
Part-D enrollees who reached prescription drug coverage gap (in-gap) versus those 
who did not (no-gap), in 2007. The study is unique because it examined characteristics 
of Medicare Part-D enrollees that are typically not available in administrative claims 
databases. METHODS: A survey based on the Seniors’ Prescription Coverage, Use 
and Spending Survey and the Brief Medication Questionnaire was developed and dis-
tributed to elderly persons seeking care at the pharmacies within the University of 
Arkansas for Medical Sciences College of Pharmacy Advanced Community Practice 
Network. Patients recruited were 65 years or older, enrolled in Medicare Part D in
2007, and taking medications for any of the following conditions: hypertension, 
hyperlipidemia, diabetes, asthma/COPD, or depression. RESULTS: In this initial
phase, 69 patients were enrolled and 24 (34.8%) reported reaching the coverage gap
in 2007. Among in-gap patients, 95% were aged 65–85 years and 58% were female, 
compared to 73% and 64% respectively for the no-gap subjects. Compared with the
no-gap subjects, more in-gap subjects attended college (78% vs. 46%), had a monthly
income of $2000 or more (70.8% vs. 56%), and spent more than $300 per month
on medications (42% vs. 24%). Compared with no-gap patients, in-gap patients were 
less likely (54% vs. 69%) to report overall satisfaction with Part-D programs. Finally, 
87.5% of the in-gap patients reached the gap in September 2007 or later. CONCLU-
SIONS: One-third of the subjects reached the coverage gap and most of them reached 
the gap within the last quarter of 2007, mitigating the impact of coverage gap to some 
extent. The in-gap group belonged to higher socioeconomic status, which was expected
since the no-gap group appeared not to be at the risk of coverage gap because of 
low-income subsidies. Experiencing coverage gap negatively impacted patients’ satis-
faction with Part-D plans.
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OBJECTIVES: Taiwan’s National Health Insurance’s (NHI) generous coverage and 
patients’ freedom to access different tiers of medical facilities has resulted in accelerat-
ing outpatient care utilisation and cost. To deter non-essential visits and encourage 
initial contact in primary care, a differential co-payment was introduced on July 15, 
2005. Under this, patients pay more for outpatient consultations at higher medical
facilities, particularly if accessed without referral. This study aimed to explore the 
impact of this policy on outpatient medical activities and expenditure, different co-
payment groups and tiers of medical facilities. METHODS: A segmented time-series 
analysis on regional weekly outpatient medical claims (January 2004 to July 2006). 
Outcome variables (number of visits, number of outpatients, total cost of outpatient 
care) and variables for cost structure were stratiﬁ ed by tiers of medical facilities and 
